Cargando…
Rapamycin improves healthspan but not inflammaging in nfκb1 (−/−) mice
Increased activation of the major pro‐inflammatory NF‐κB pathway leads to numerous age‐related diseases, including chronic liver disease (CLD). Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF‐...
Autores principales: | Correia‐Melo, Clara, Birch, Jodie, Fielder, Edward, Rahmatika, Dina, Taylor, Jennifer, Chapman, James, Lagnado, Anthony, Carroll, Bernadette M., Miwa, Satomi, Richardson, Gavin, Jurk, Diana, Oakley, Fiona, Mann, Jelena, Mann, Derek A., Korolchuk, Viktor I., Passos, João F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351839/ https://www.ncbi.nlm.nih.gov/pubmed/30468013 http://dx.doi.org/10.1111/acel.12882 |
Ejemplares similares
-
Mitochondria in Cell Senescence: Is Mitophagy the Weakest Link?
por: Korolchuk, Viktor I., et al.
Publicado: (2017) -
Transient and late-life rapamycin for healthspan extension
por: Quarles, Ellen K., et al.
Publicado: (2020) -
Evaluation of off-label rapamycin use to promote healthspan in 333 adults
por: Kaeberlein, Tammi L., et al.
Publicado: (2023) -
Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice
por: Fielder, Edward, et al.
Publicado: (2022) -
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
por: Bitto, Alessandro, et al.
Publicado: (2016)